Abstracts tagged "Activity score"

Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Manuel Ugarte-Gil^1,2, Ines Segami^3,4, Guillermina Harvey⁵, Guillermo J. Pons-Estel⁶, Rosana Quintana⁷, Cristina Reategui-Sokolova⁸, Jorge Cieza⁴, Luis J. Catoggio⁹, Mercedes Garcia¹⁰, Verónica Saurit¹¹, Francisco Caeiro¹², Cristina Drenkard¹³, Guillermo Berbotto¹⁴, Emilia Sato¹⁵, Lilian Costallat¹⁶, Eloisa Bonfa¹⁷, Joao C. Tavares Brenol¹⁸, Nilzio A Da Silva¹⁹, Fernando Cavalcanti²⁰, Antonio Iglesias-Gamarra²¹, Marlene Guibert-Toledano²², Gil A. Reyes²², Loreto Massardo²³, Oscar J Neira²⁴, Mario H Cardiel²⁵, Leonor Barile²⁶, Mary Carmen Amigo²⁷, Luis H. Silveira²⁸, Ignacio Garcia de la Torre²⁹, Eduardo Acevedo-Vasquez², Rosa Chacón-Díaz³⁰, Maria H Esteva Spinetti³¹, Graciela S. Alarcón^32,33 and Bernardo A Pons-Estel⁷, ¹Rheumatology, Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁴Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, ⁵Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ⁸Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁹Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ¹¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹²Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹³Medicine/Rheumatology, Emory University, Atlanta, GA, ¹⁴Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁵Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹⁶Universidade Estadual da Campinas, Campinas, Brazil, ¹⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹⁸Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, ¹⁹Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, ²⁰Universidade Federal da Pernambuco, Pernambuco, Brazil, ²¹Universidad Nacional de Colombia, Bogota, Colombia, ²²Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, ²³Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, ²⁴Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ²⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²⁶Hospital Ángeles del Pedregal, Mexico, Mexico, ²⁷Rheumatology, Centro Medico ABC, Mexico, Mexico, ²⁸Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ²⁹Hospital General de Occidente, Guadalajara, Mexico, ³⁰Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ³¹Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), ³²Universidad Peruana Cayetano Heredia, Lima, Peru, ³³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…
Abstract Number: 463 • 2018 ACR/ARHP Annual Meeting
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
Pooja Patel¹, Marietta M. De Guzman¹, Joseph Maliakkal², Michelle Rheault³, David Selewski⁴, Katherine Twombley⁵, Jason Misurac⁶, Cheryl Tran⁷, Alexandru Constantinescu⁸, Ali Mirza Onder⁹, Meredith Seamon¹⁰, Vaishali Singh¹¹, Cynthia Pan¹¹, Joseph Flynn¹², Abiodun Omoloja¹³, William Smoyer¹⁴, Guillermo Hidalgo¹⁵ and Scott E. Wenderfer¹⁶, ¹Pediatrics-Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatrics-Renal, Saint Louis University, St. Louis, MO, ³Pediatrics-Renal, University of Minnesota, Minneapolis, MN, ⁴Pediatrics-Renal, University of Michigan, Ann Arbor, MI, ⁵Pediatrics-Renal, Medical University of South Carolina, Charleston, SC, ⁶Pediatrics-Renal, University of Iowa, Iowa City, IA, ⁷Pediatrics-Renal, Mayo Clinic, Rochester, MN, ⁸Pediatrics-Renal, Joe DiMaggio Children’s Hospital, Hollywood, FL, ⁹Pediatrics-Renal, University of Tennessee, Memphis, TN, ¹⁰Pediatrics-Renal, The University of Utah, Salt Lake, UT, ¹¹Pediatrics-Renal, Medical College of Wisconsin, Wauwatosa, WI, ¹²Pediatrics-Renal, Seattle Children's Hospital, Seattle, WA, ¹³Pediatrics-Renal, Wright State University, Dayton, OH, ¹⁴Pediatrics-Renal, Nationwide Children’s Hospital, Columbus, OH, ¹⁵Pediatrics-Renal, East Carolina University, Greenville, NC, ¹⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Outcomes for childhood-onset crescentic lupus nephritis are unclear. The revised classification system for lupus nephritis by the Renal Pathology Society clearly distinguishes between cellular,…
Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Genki Kidoguchi¹ and Kenichiro Tokunaga², ¹General internal medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…
Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Adeeba Al-Herz¹, Khulood Saleh², Adel Al-Awadhi³, Waleed Al-Kandari², Eman Hasan⁴, Aqeel Ghanem⁵, Yaser Ali⁵, Hebah Alhajeri⁶, Sawsan Hayat⁵, Ali Aldei⁷, Mohammad Hussain⁴, Ibrahim Nahar⁵, Fatemah Abutiban⁸, Ahmad Alenizi⁸, Khaled Mokaddem¹, Ahmad Khadrawy², Ammad Fazal², Agaz Zaman⁵, Ghada Mazloum⁵, Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁸ and Ahmed Al-Saber⁹, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Farwania Hospital, Farwania, Kuwait, ³Faculty of Medicine, Kuwait, Kuwait, ⁴Al-Amiri Hospital, Kuwait city, Kuwait, ⁵Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ⁶Division of Rheumatology, Mubarak Al-Kabeer Hospital, hawalli, Kuwait, ⁷Rheumatology, Al-Amiri Hospital, Kuwait City, Kuwait, ⁸Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁹Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…
Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Laura C. Coates², Ana-Maria Orbai³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Laure Gossec²², ¹Sorbonne Université, PARIS, France, ²University of Oxford, Oxford, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Sorbonne Universités, Paris, France
Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
Abstract Number: 930 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study
Marianna Meroni¹, Véronique Laure Ramoni², Massimiliano Parodi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Division of Rheumatology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ³Rheumatology Unit, Internal Medicine Department, A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) can affect young women and pregnancy still represents a challenge. Prednisone is safely used, at low doses (<7.5 mg daily),…
Abstract Number: 1431 • 2017 ACR/ARHP Annual Meeting
Serum Trough Levels of Adalimumab Inversely Correlate with Disease Activity in Patients with Inflammatory Arthritis
Daman Langguth¹, Peter Wong², Alison Bowling³, Hanish Bagga⁴, Di Freeman⁴ and emma ford⁵, ¹Immunology, Sullivan Nicolaides Pathology, Brisbane, Australia, ²Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ³School of health and human sciences, Southern Cross University, Coffs Harbour, Australia, ⁴Mid-North Coast Arthritis Clinic, Coffs Harbour, Australia, ⁵Mid North Coast Arthritis Clinic, Coffs Harboyr, Australia
Background/Purpose: Targeted blockade of TNF has been a major advance in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). However,…
Abstract Number: 1498 • 2017 ACR/ARHP Annual Meeting
Long-Term Cohort of Patients with a Clinical Diagnosis of Sjogren’s Syndrome: Activity Index and Patient Reported Outcome Performance
Anna Viola Taulaigo¹, Maria Francisca Moraes-Fontes¹, Melissa Fernandes², Vera Bernardino² and Tiago Ramires³, ¹Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, ²Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisboa, Portugal, ³Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal; Serviço de Medicina Interna, Hospital Espírito Santo, Évora, Portugal, Lisbon, Portugal

Background/Purpose: There have been three classification proposals for Sjögren´s Syndrome (SS) over the past 15 years (1-3). The 2016 criteria require a diagnostic work-up which…
Abstract Number: 2141 • 2017 ACR/ARHP Annual Meeting
Quantitative Nailfold Video Capillaroscopy Parameters Correlate with Dermatomyositis Activity and Damage
Hans Prakash¹, Diego Song¹, Daniel Lichy¹, Pranay Rao², Mina Jain³, Joseph Shrader³, Frederick W Miller⁴, Adam Schiffenbauer⁵, Alexander Gorbach¹ and Lisa G Rider⁵, ¹National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, ²National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, bethesda, MD, ³Rehabilitation Medicine Department, National Institutes of Health, Bethesda, MD, ⁴Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁵Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: To assess microvascular structure and function in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM), we have designed and built a mobile, high-resolution…
Abstract Number: 2630 • 2017 ACR/ARHP Annual Meeting
Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus
Eun Young Ahn¹, Wonho Lee², Jin Young Moon², Jin Kyun Park², Eun Young Lee³, Eun Bong Lee², Sang-Cheol Bae⁴ and Kichul Shin⁵, ¹Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea., Seoul, Korea, Republic of (South), ⁴Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Assessing patient-reported outcomes validated to be associated with disease activity has helped clinicians better understand treatment response of patients with systemic rheumatic disease. Such…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 882 • 2016 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Valerie Devauchelle^1,2, Lea Saraux³, Jean-Marie Berthelot⁴, Divi Cornec⁵, Thierry Marhadour⁶, Sandrine Jousse-Joulin⁷, Michel De Bandt⁸, Maelenn Gouillou⁹ and Alain Saraux¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ²Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Department of rheumatology, Brest Occidentale University, Brest, France, ⁶Rheumatology, CHU La Cavale Blanche, Brest, France, ⁷Rheumatology, CHu La cavle Blanche, Brest, France, ⁸CHU Fort de France, Fort de France, France, ⁹Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ¹⁰Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France

Background/Purpose: Disease activity of polymyalgia rheumatica (PMR) (1, 2) may be evaluated using the PMR activity score (PMR-AS). For patients without measure of CRP, or patients…
Abstract Number: 1723 • 2016 ACR/ARHP Annual Meeting
Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice
Maria Laura Acosta Felquer¹, Agnes Szentpetery^2,3,4,5, Musaab Elmamoun⁶, Phil Gallagher⁴, Oliver FitzGerald⁷ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁵Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁶Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ⁷St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

Background/Purpose: The Composite Psoriatic Disease Activity Index (CPDAI), a composite disease outcome measure in psoriatic arthritis (PsA) (1),has proved to be a valid and discriminative…
Abstract Number: 1841 • 2016 ACR/ARHP Annual Meeting
Dysregulation of the Splicing Machinery Components in Leukocytes from Patients with Systemic Lupus Erythematosus: Influence on Autoimmune and Atherothrombotic Mechanisms
Chary Lopez-Pedrera¹, Sergio Pedraza-Arévalo², Mercedes del Río-Moreno², Maria Ángeles Aguirre Zamorano¹, Patricia Ruiz-Limon³, Nuria Barbarroja¹, Yolanda Jiménez-Gómez¹, Ivan Arias de la Rosa³, Eduardo Collantes-Estévez¹, Pedro Segui¹, Maria Jose Cuadrado⁴, Justo P Castaño², Raul M Luque² and Carlos Perez-Sanchez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Department of Cell Biology, Physiology and Immunology. University of Cordoba, Hospital Universitario Reina Sofia (HURS), Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), CIBERobn, and ceiA3, Córdoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: The aim of this study was to evaluate whether alterations in the splicing-machinery could influence the development and activity of the disease and the…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].